Home › MannKind's Afrezza Remains in Sanofi's Plans, RBC Says
 

Keywords :   


MannKind's Afrezza Remains in Sanofi's Plans, RBC Says

2014-11-22 19:25:26| Biotech - Topix.net

Yesterday, Sanofi hosted a seminar on new medicines in Cambridge, Mass., and RBC's Adnan Butt and team note that MannKind's inhaled insulin Afrezza "featured prominently enough." They summarize the highlights of the presentation: MannKind's partner reiterated prior guidance that a commercial launch is planned for 1Q:15.

Tags: plans says remains rbc

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
26.06Atlantic Tropical Weather Outlook
26.06Eastern North Pacific Tropical Weather Outlook
26.06XREAL bring Play Store apps to 3D space on XREAL AR glasses
26.06Qwilt reveals live streaming survey results
26.06Rockline Industries Wins WOW Innovation Award
26.06IMS Technologies Expands Calcinate Production Site
26.06Horizon expert 'gave evidence based on informal chats'
26.06Automotive Color by BASF Recognized with Renowned Red Dot Award
More »